This publication was funded by Boehringer Ingelheim Pharmaceuticals, Inc.
Insights gained over the past two decades about idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILD) have greatly advanced our understanding of these conditions and have helped facilitate earlier diagnosis and intervention and improvements to patient care. Recently, the concept of progressive fibrosing ILD has emerged, as many patients with fibrosing ILDs show rapid deterioration similar to IPF, thereby requiring close monitoring.
This publication explores fibrosing ILDs, in recognition of the need for further education about these conditions.
